A simple test using an MRI scan can be used to predict how well people with advanced ovarian cancer will respond to treatment, according to the results of a new study.

A new type of drug that blocks one of cancer’s key evolutionary escape routes from chemotherapy could be used to treat aggressive breast cancers, a new study has shown.

The ICR responds to the approval by NHS regulators NICE for the use of targeted cancer drug olaparib earlier in the course of treatment for women with late-stage ovarian cancer and other gynaecological cancers who have BRCA gene mutations.